美国强直性脊柱炎与非放射学中轴型脊柱关节炎的合并症与治疗比较
本研究利用美国两家学术医院电子病历开展横断面研究,比较AS与nr-axSpA患者的合并症和bDMARD使用情况。在965例患者中,80%分类为axSpA,AS患者年龄更大、男性更多、炎症标志物更高,但两组合并症负担和bDMARD使用史相似。
要点
- AS与nr-axSpA患者合并症平均数量相似(1.5,s.d. 2.2),约半数患者至少有一种合并症。
- 两组bDMARD使用史无差异(55%),最常用为阿达木单抗(31%)和依那西普(29%)。
- AS患者较nr-axSpA年龄更大(54 vs 46岁)、男性更多(77% vs 64%)、CRP更高(中位3.4 vs 2.2 mg/dl)。
核心结论
- 尽管存在年龄差异,nr-axSpA患者与AS患者具有相似的合并症负担。
- 在美国临床队列中,两组接受了相当的bDMARD治疗。
研究设计与样本
- 横断面研究,使用美国两家学术医院的电子病历数据。
- 通过自动化搜索(≥3个ICD编码结合文本搜索)提取数据,并辅以人工病历回顾。
- 共识别965例患者,其中775例(80%)分类为axSpA。
主要发现
- 队列以男性为主(74%),平均年龄52.5岁(s.d. 16.8)。
- AS患者较nr-axSpA显著年龄更大(54 vs 46岁)、男性更常见(77% vs 64%)、血清炎症标志物更高(中位CRP 3.4 vs 2.2 mg/dl)。
- 半数患者至少有一种合并症,平均合并症数量为1.5(s.d. 2.2),AS与nr-axSpA组间相似。
- 55%患者有bDMARD使用史,两组间无差异;最常用bDMARD为阿达木单抗(31%)和依那西普(29%),各bDMARD曾用处方在两组间相似。
关键数值与推荐
- 患者根据分类标准分为AS或nr-axSpA。
- 合并症来自39种慢性病列表。
- bDMARD使用史通过处方记录评估。
临床怎么用
- 在临床实践中,nr-axSpA患者应像AS患者一样评估合并症负担。
- bDMARD选择在AS与nr-axSpA之间可参照相似的治疗模式。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to compare comorbidities and biologic DMARD (bDMARD) use between AS and non-radiographic axial SpA (nr-axSpA) patients, using a large cohort of patients from routine clinical practice in the United States. METHODS: We performed a cross-sectional study using electronic medical records from two academic hospitals in the United States. Data were extracted using automated searches (⩾3 ICD codes combined with text searches) and supplemented with manual chart review. Patients were categorized into AS or nr-axSpA according to classification criteria. Disease features, comorbidities (from a list of 39 chronic conditions) and history of bDMARD prescription were compared using descriptive statistics. RESULTS: Among 965 patients identified, 775 (80%) were classified as having axSpA. The cohort was predominantly male (74%) with a mean age of 52.5 years (s.d. 16.8). AS patients were significantly older (54 vs 46 years), more frequently male (77% vs 64%) and had higher serum inflammatory markers than those with nr-axSpA (median CRP 3.4 vs 2.2 mg/dl). Half of all patients had at least one comorbidity. The mean number of comorbidities was 1.5 (s.d. 2.2) and similar between AS and nr-axSpA groups. A history of bDMARD-use was seen in 55% of patients with no difference between groups. The most commonly prescribed bDMARDs were adalimumab (31%) and etanercept (29%). Ever-prescriptions of individual bDMARDs were similar between AS and nr-axSpA. CONCLUSION: Despite age differences, nr-axSpA patients had similar comorbidity burdens as those with AS. Both groups received comparable bDMARD treatment in this United States clinic-based cohort.
引用
- Zhao SS, Ermann J, Xu C, et al. Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States. Rheumatology (Oxford). 2019. PMID: 31081033. doi:10.1093/rheumatology/kez171
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。